Cell line · CVCL_0620
Papers69
1 to 20 of 69
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PatientProfiler: building patient-specific signaling models from proteogenomic data. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GRB2 is a BECN1 interacting protein that regulates autophagy. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0620/papers